Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
893 S Delaware St
Indianapolis, IN 46285
  • Featured Employer
Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
  • “Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”
    Kavita - Associate Director, Packaging Operations
  • “Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”
    Adrian - Associate Director, IDM
  • “What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”
    Cecile - Sr Director, Design Hub Foundations
39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.
NEWS
After last week’s avalanche of clinical trial news associated with the American Society of Hematology Annual Meeting, there are far fewer announcements, but some companies are getting their news out ahead of the holidays.
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
The new funding will allow the biotech company to advance its programs and accelerate the development of life-saving treatments for neurodegenerative diseases.
Eli Lilly and Company’s projections for next year exceed Wall Street projections for the company, predicting 2022 revenue of $27.8 billion to $28.3 billion.
The FDA approved the latest indication for Rinvoq (upadacitinib) based on data from two Phase III studies, SELECT-PsA 1 and SELECT-PsA 2.
These results set Lilly up well to submit a Biologics License Application (BLA) in the first half of 2022.
A member of BioSpace’s Class of 2021, CODA aims to modify neuronal cell populations using gene therapy to express a tunable ligand-gated ion channel.
The collaboration covers the co-development and co-commercialization of products created from Foghorn’s BRM oncology program and another oncology target.
Eli Lilly forged a multi-year collaborative partnership with China-based Regor Therapeutics Group to discover and develop new therapies that will be aimed at metabolic disorders.
JOBS
IN THE PRESS